Epredia’s E1000 Dx Digital Pathology Solution Wins 2025 International Scanner Benchmark Awards from the Ecosystem for Pathology Diagnostics with AI Assistance (EMPAIA)

September 29, 2025

RUNCORN, United Kingdom--(BUSINESS WIRE)--The Ecosystem for Pathology Diagnostics with AI Assistance (EMPAIA), an international organization that advances the use of validated AI solutions in clinical practice, has announced that Epredia, a global leader in precision cancer diagnostics, has won three categories in the 2025 International Scanner Benchmark (ISB) for Epredia’s E1000 Dx Digital Pathology Solution. The ISB recognizes excellence in quality, throughput, and design of digital slide scanning technology for pathology.

The E1000 Dx consists of a high-speed, automated, whole-slide imaging digital scanner with medical grade viewer and advanced image management and viewer software that creates high-resolution digital images of up to 1,500 tissue samples daily. The E1000 Dx is designed to maximize laboratory throughput and efficiency with technology advancements in sample detection and quality control procedures, which has the potential to make diagnostics more efficient and accurate.

EMPAIA supports regulatory, legal, technical, and organizational pathways to the adoption of validated and certified AI solutions. Through the ISB, EMPAIA seeks to identify the pathology industry’s top image-based diagnostics technologies, which provide detailed digital images that are critical inputs for potential future AI-powered diagnostics.

Epredia’s E1000 Dx won the 2025 ISB in the categories of Quality for digital images at 20x magnification, and Quality and High Throughput for digital images at 40x magnification, the highest level of magnification tested. The honors were based on a comprehensive and objective scanner evaluation, performed on samples from a variety of laboratories across Europe and reviewed by a panel of pathologists. Winners were awarded at the 37th European Congress of Pathology in Vienna, Austria, in September.

Epredia’s E1000 Dx builds on technology originally developed by 3DHISTECH, a leading pathology and diagnostics company and close commercial partner of Epredia. 3DHISTECH also received top honors in the ISB for its Pannoramic 480 Dx digital slide scanner, in the categories of High Throughput for digital images at 20x magnification and Technical capabilities, as well as being recognized with the prestigious Innovator 2025 Award. Epredia is a distributor of the full 3DHISTECH digital pathology portfolio including the Pannoramic 480 Dx.

Steven Lynum, President of Epredia, said, "Digital pathology is the future of cancer diagnostics. As pathology laboratories face greater pressure to speed up processes and reduce costs, we are deeply honored that EMPAIA has recognized the E1000 Dx as a leader in both high throughput and quality. AI holds tremendous potential to enhance the way conditions like cancer are diagnosed and ultimately treated, but AI is only as powerful as the images available to analyze. We look forward to Epredia and 3DHISTECH solutions helping laboratories maximize their digital pathology investment today as well as the potential of this technology to support AI-powered diagnostics in the future."

Su Epredia

Epredia è leader mondiale nel settore della patologia anatomica e fornisce soluzioni complete per la diagnostica oncologica e tissutale di precisione. Grazie a marchi importanti, tra cui Erie Scientific, Menzel-Gläser, Microm, Shandon e Richard-Allan Scientific, il portafoglio di Epredia comprende vetrini per microscopio, strumenti e materiali di consumo. Epredia è stata fondata in seguito all'acquisizione delle attività di anatomia patologica di Thermo Fisher Scientific’da parte di PHC Holdings nel 2019. Epredia è presente nei principali siti di Stati Uniti, Regno Unito, Germania, Svizzera e Cina con un totale di circa 1.200 dipendenti. Epredia è impegnata a realizzare la sua missione di migliorare la vita dei pazienti di tutto il mondo attraverso il potenziamento della diagnostica oncologica. Per ulteriori informazioni su Epredia e i suoi prodotti, visitare il sito www.epredia.com.

Sulla PHC Holdings Corporation (PHC Group)

PHC Holdings Corporation (TSE 6523) è un'azienda sanitaria globale con la missione di contribuire alla salute della società attraverso soluzioni sanitarie che abbiano un impatto positivo e migliorino la vita delle persone. Le sue consociate (indicate collettivamente come PHC Group) comprendono PHC Corporation, Epredia, Ascensia Diabetes Care, LSI Medience Corporation, Mediford e Wemex. Insieme, queste società sviluppano, producono, vendono e forniscono assistenza per soluzioni di gestione del diabete, soluzioni sanitarie, scienze della vita e diagnostica. Il fatturato netto consolidato di PHC Group’nell'anno fiscale 2022 è stato di 356,4 miliardi di JPY con una distribuzione globale di prodotti e servizi in oltre 125 Paesi.
www.phchd.com

Per ulteriori informazioni, contattare:

Julia Cottrill
PHC Group Corporate Communications
Email: julia.cottrill@phchd.com